Literature DB >> 23438693

Mdm2 increases cellular invasiveness by binding to and stabilizing the Slug mRNA.

Chan-Hun Jung1, Jongdoo Kim, Jong Kuk Park, Sang-Gu Hwang, Sung-Kwon Moon, Wun-Jae Kim, Hong-Duck Um.   

Abstract

Mdm2 is an oncoprotein that induces the degradation of the tumor suppressor, p53. Here, we show that Mdm2 increases the mRNA levels of Slug by binding to and stabilizing the Slug mRNA. While this effect of Mdm2 was observed in both p53-null and p53-expressing cancer cells, it increased the protein levels of Slug only in the former cells. Mdm2 consistently induced Slug-dependent events, such as decreases in E-cadherin levels and increases in cellular invasiveness, only in p53-null cells. Therefore, the binding of Mdm2 to the Slug mRNA appears to provide a novel mechanism through which Mdm2 promotes tumor progression in a manner independent of the presence of p53.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23438693     DOI: 10.1016/j.canlet.2013.02.035

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  17 in total

1.  MiR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling pathway.

Authors:  Bo Wang; Zhan-long Shen; Zhi-dong Gao; Gang Zhao; Chun-you Wang; Yang Yang; Ji-zhun Zhang; Yi-chao Yan; Chao Shen; Ke-wei Jiang; Ying-jiang Ye; Shan Wang
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Cryptic in vitro ubiquitin ligase activity of HDMX towards p53 is probably regulated by an induced fit mechanism.

Authors:  Karla Gisel Calderon-González; Ixaura Medina-Medina; Lucia Haronikova; Lenka Hernychova; Ondrej Bonczek; Lukas Uhrik; Vaclav Hrabal; Borivoj Vojtesek; Robin Fahraeus; Jesús Hernández-Monge; Vanesa Olivares-Illana
Journal:  Biosci Rep       Date:  2022-07-29       Impact factor: 3.976

Review 3.  Opposing Roles of Wild-type and Mutant p53 in the Process of Epithelial to Mesenchymal Transition.

Authors:  Oleg Semenov; Alexandra Daks; Olga Fedorova; Oleg Shuvalov; Nickolai A Barlev
Journal:  Front Mol Biosci       Date:  2022-06-23

4.  Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment.

Authors:  Lubing Gu; Hailong Zhang; Tao Liu; Sheng Zhou; Yuhong Du; Jing Xiong; Sha Yi; Cheng-Kui Qu; Haian Fu; Muxiang Zhou
Journal:  Cancer Cell       Date:  2016-09-22       Impact factor: 31.743

Review 5.  p53-independent effects of Mdm2.

Authors:  Stephen Bohlman; James J Manfredi
Journal:  Subcell Biochem       Date:  2014

Review 6.  Targeting MDM2 for novel molecular therapy: Beyond oncology.

Authors:  Wei Wang; Jiang-Jiang Qin; Mehrdad Rajaei; Xin Li; Xiaoyi Yu; Courtney Hunt; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2019-10-06       Impact factor: 12.944

7.  Slug expression in mouse skin and skin tumors is not regulated by p53.

Authors:  Carlos J Perez; Joyce E Rundhaug; David G Johnson; Tatiana M Oberyszyn; Kathleen L Tober; Donna F Kusewitt
Journal:  J Invest Dermatol       Date:  2013-09-05       Impact factor: 8.551

8.  Inhibition of MDM2 homodimerization by XIAP IRES stabilizes MDM2, influencing cancer cell survival.

Authors:  Tao Liu; Hailong Zhang; Jing Xiong; Sha Yi; Lubing Gu; Muxiang Zhou
Journal:  Mol Cancer       Date:  2015-03-26       Impact factor: 27.401

9.  Involvement of SULF2 in y-irradiation-induced invasion and resistance of cancer cells by inducing IL-6 expression.

Authors:  Chan-Hun Jung; Jin-Nyoung Ho; Jong Kuk Park; Eun Mi Kim; Sang-Gu Hwang; Hong-Duck Um
Journal:  Oncotarget       Date:  2016-03-29

10.  A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo.

Authors:  D F Comiskey; A G Jacob; B L Sanford; M Montes; A K Goodwin; H Steiner; E Matsa; A S Tapia-Santos; T W Bebee; J Grieves; K La Perle; P Boyaka; D S Chandler
Journal:  Oncogene       Date:  2017-09-11       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.